Most people have heard of collagen. Far fewer people know there are multiple types of collagen — and that the type matters enormously when we’re talking about regenerative biologics.
The three types most relevant to joints
Type 1 is the most abundant collagen in the body. It forms the structural backbone of tendons, ligaments, skin, bone, and many of the soft structures inside your joints, including the ACL and the meniscus. It’s essentially the cable and fiber of your structural tissue.
Type 2 lives in a different neighborhood. It’s the dominant collagen in articular cartilage — the smooth, glistening surface that caps the ends of bones at every joint. When people talk about cartilage “wearing down,” Type 2 collagen is what’s being depleted.
Type 3 typically works in tandem with Type 1. It’s especially important during the repair process, providing scaffolding while permanent tissue is being laid down. Tissues rich in Type 3 tend to be elastic and reparative.
Why this matters for regenerative biology
When a biologic is placed in the body, your own cells respond to the structural proteins it contains. They produce more of whatever collagen type the biologic supplies. This is called collagenic differentiation, and it’s one of the more elegant findings in regenerative science.
The practical implication: if a biologic contains primarily Type 1 collagen, your body produces a primarily Type 1 response. Useful for tendons and ligaments. Less complete for cartilage.
The autologous vs. allogeneic collagen profile
Platelet-rich plasma (PRP) and bone marrow concentrate (BMAC) are autologous — made from your own body. Both are predominantly Type 1 collagen-rich.
Wharton’s Jelly, derived from umbilical cord tissue donated after full-term C-section deliveries, contains Types 1, 2, AND 3 collagen — plus hyaluronic acid. The collagen profile is more comprehensive.
What this looks like in published research
A 2022 study referenced in regenerative literature placed articular cartilage — Type 2 collagen — in a petri dish alongside Wharton’s Jelly tissue. Researchers used histologic and immunofluorescent staining to assess collagenic differentiation. The result was a more complete collagenic response than tissue alone or other simpler biologics produced.
This is the kind of receipt our medical team looks for. Peer-reviewed, published work in indexed journals — the type of validation Dr. Scott Martin and other regenerative experts have advocated for as the standard for any product worth taking seriously.
What patients can ask
If you’re evaluating a regenerative consultation, the collagen profile question is a fair one to raise:
What collagen types does the biologic you’re recommending contain? What collagen type is the tissue we’re trying to support? Is there a published study you can show me on this specific product?
A confident provider should welcome those questions. A reluctant one tells you what you need to know.
The bigger principle
Regenerative biologics are not interchangeable. Knowing the difference between collagen types isn’t academic trivia — it’s the foundation of matching the right material to the right tissue. Our medical team builds every protocol around the structural reality of the tissue being supported, not around marketing language about a product.
REQUIRED DISCLAIMER
Educational content only. The information presented in this article is for general informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. RegenHaus uses 361 HCT/P regenerative biologics, which are not FDA-approved to treat or cure any condition. Individual results vary. Please consult a licensed medical provider before considering any therapy or making changes to your health regimen.
